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Objective In systemic lupus erythematosus (SLE) patients, excessive formation of neutrophil 
extracellular traps (NETs) is observed and their degradation is impaired. In vitro, immune complexes 
(ICx) trigger NET formation while NET-derived DNA is a postulated autoantigen for anti-nuclear 
autoantibodies (ANAs), found in SLE. Based on these self-perpetuating mechanisms in SLE, this study 
investigates whether interfering with ICx formation using a combination of rituximab (RTX) and 
belimumab (BLM) could decrease NET formation and ameliorate disease.    
 
Methods A phase 2A, open-label, single arm proof-of-concept study was performed wherein 16 SLE 
patients with severe, refractory disease were treated with a combination of CD20-mediated B-cell 
depletion with rituximab and sustained inhibition of B-cell activating factor BlyS with belimumab.  
Besides safety, the study’s endpoints were chosen to address the concept of autoantibodies in 
relation to excessive NET formation. 
 
Results We demonstrated a surge of BlyS levels upon RTX-mediated B-cell depletion which was 
abrogated by subsequent BLM treatment.. As such, therapeutic intervention with RTX+BLM led to 
specific reductions in ANAs and regression of excessive NET formation. RTX+BLM appeared to be 
safe and achieved clinically significant responses: low lupus disease activity state was achieved in 10 
patients, renal responses in 11 patients and concomitant immunosuppressive medication was 
tapered in 14 out of the 16 patients. 
 
Conclusions This study provides novel insights into clinical beneficence of reducing excessive NET 
formation in SLE by therapeutic targeting ANA production with RTX+BLM. Altogether putting 
forward a new treatment concept that specifically ameliorates underlying SLE pathophysiology. 
 




I. Combination treatment of rituximab with belimumab leads to significant reductions of 
autoantibodies and consequently regression of excessive NET formation.  
II. Combined B cell targeted therapy affects neutrophil-derived autoantigens.  
III. Combination therapy led to significant clinical responses in previous refractory patients 
while reducing other immunosuppressive drugs 
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Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the loss of 
tolerance to nucleic acids and their binding proteins. This results in the generation of anti-nuclear 
autoantibodies (ANAs), including anti-dsDNA, anti-chromatin and anti-histone autoantibodies. 
Neutrophil extracellular traps (NETs) have been demonstrated as prominent autoantigens leading to 
disease-relevant autoantibody production[1–8] . Excessive NET formation [9] together with the 
impaired degradation of NETs [10,11] has been associated with disease severity in SLE including the 
presence of lupus nephritis (LN), anti-dsDNA levels and complement usage[11]. The triggers of 
excessive NET formation in SLE have been associated with anti-RNP[4] and anti-LL37[2] 
autoantibodies. Moreover, the impaired degradation of NETs is also associated with DNA-binding 
autoantibodies that block access for the DNAse-I complex which is functionally intact in SLE [12]. So, 
regression of excessive NET formation has been postulated as an important therapeutic goal in SLE 
[13]. 
 
Additional to NETs, which are proposed as important autoantigens for the development of ANAs, SLE 
patients display characteristics of B-cell hyperactivity[14] including the typical increase in circulating 
plasma cells[15,16]. Despite the eminent role of autoreactive B-cells in SLE, specific targeting of B-
cells with rituximab (RTX) has been unsuccessful in randomized trials[17,18]. The well-described 
surge in circulating B-cell activating factor (BAFF) after B-cell depletion has been postulated to 
influence repopulation of autoreactive B-cells [19] and negatively impact the efficacy of rituximab 
[20,21]. The pathophysiological importance of BAFF is further supported by the increased serum 
BAFF levels in SLE patients compared to healthy subjects [22,23] and its association with disease 
activity [24], disease relapse [20] and  increased numbers of circulating plasma cells [25]. The 
recently approved anti-BAFF monoclonal antibody, belimumab (BLM), [26], is able to specifically 
target these pathophysiological processes in SLE subsequent to rituximab treatment. Interestingly, a 
few case reports have reported the clinical use of combined anti-CD20 and anti-BAFF treatment in 
patients [27–30]: three of the cases had refractory lupus nephritis (LN) showing beneficial effects in 
response to combination therapy. 
 
The present proof-of-concept study was designed to investigate the hypothesis that combination 
treatment of rituximab with belimumab (RTX+BLM) would have a synergetic reducing effect on 
autoantibody production and thereby diminishing NET formation in SLE patients. As a novel 
therapeutic approach in SLE, this proof-of-concept study was designed as a single-arm translational 
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study aimed at determining the immunological effects while simultaneously evaluating safety and 




2. Materials and methods 
2.1. Clinical study 
We conducted a phase 2, single-arm, proof-of-concept study in which SLE patients were included 
who had severe and refractory disease. 'Severe SLE' was defined as an SLE disease activity index 
(SLEDAI) score of 12 or more points or new, worse, or persistent SLE-related activity in major organs. 
Refractory disease was defined according to national Dutch guidelines[31]: 1) the failure of initial 
induction treatment for which a switch to another induction therapy regimen was already carried 
out; 2) intolerance or contraindication for cyclophosphamide and mycophenolate mofetil (MMF); 3) 
a second relapse within two years after the start of initial induction therapy; or 4) a relative 
contraindication for high-dose oral or intravenous prednisone. A renal biopsy was performed in 2 
refractory LN patients prior to inclusion where the diagnosis active LN was uncertain. Patients were 
excluded if pregnant, had low peripheral B-cell counts (<60x106 cells/liter), hypogammaglobulinemia 
(IgG<4.0 g/l), IgA deficiency (IgA<0.1 g/l), active infection or a history of primary immunodeficiency 
or active malignancy in the past 5 years.  
Patients were treated with 1000 mg RTX at weeks 0 and 2 and with 10 mg/kg BLM at weeks 4, 6, 8 
and then every 4 weeks. In accordance with international guidelines[32], any patient with active 
lupus nephritis or severe neurological involvement (e.g. transverse myelitis) received concomitant 
intravenous methylprednisolone pulse therapy (variable dose/regimens). High dose glucocorticoids 
were started at 1 mg/kg (maximum dose was 60 mg per day) and tapered towards a maintenance 
dose of 7.5 mg/day. The study was approved by the LUMC medical ethics committee and all patients 
provided written informed consent. The study was registered at ClinicalTrials.gov (NCT02284984).  
 
2.2. Endpoints 
Primary endpoints were decrease in autoantibodies and NET formation at 24 weeks. Secondary 
outcomes were seroconversion of anti-dsDNA autoantibodies, complement normalization, safety, 
feasibility, and clinical response. Autoantibodies were measured at screening, baseline and at 4, 12, 
and 24 weeks. Ex vivo NET induction was determined at screening, at week 12 and at week 24. 
Clinical response was investigated by determining the SLEDAI-2000 (SLEDAI-2K) [33] and the number 
of patients that achieved lupus low disease activity state (LLDAS) after 24 weeks. LLDAS was defined 
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according to recent international recommendations[34]: 1) SLEDAI-2K ≤4, with no activity in major 
organ systems; 2) no new lupus disease activity; 3) physician global assessment ≤1; 4) prednisolone 
dose ≤7.5 mg per day; and 5) well-tolerated treatment with immunosuppressive drugs and/or 
biological agents[34]. In patients with lupus nephritis, renal responses were defined as follows: a 
complete renal response was achieved when proteinuria decreased to ≤0.7 g/24h and normal serum 
albumin, stable kidney function and a normal urinary sediment were achieved. Partial renal response 
was achieved when proteinuria: >0.7-2.9 g/24h with a decrease in proteinuria of ≥50% from 
baseline, serum albumin >30 g/l and a stable kidney function as measured by serum creatinine. 
Urine sediment did not necessarily had to be normalized for achieving a partial renal response. All 
other patients were considered to be renal non-responders. 
 
2.3. Preparation of neutrophils and ex vivo NET induction 
Whole blood (20 ml) from healthy donors was collected into EDTA-coated tubes (BD, Franklin Lakes, 
NJ, USA). Neutrophils were isolated by density gradient centrifugation with a Ficoll-amidotrizoate 
gradient (LUMC, Leiden, The Netherlands) followed by erythrocyte lysis at 4°C. Cells were counted 
using trypan blue, labelled with PKH26 (2 µM, Sigma-Aldrich, Saint-Louis, MO, USA), and 37,500 
neutrophils per well were seeded into a 96-well culture plate (Falcon, Tewksbury, MA, USA) in 
phenol red-free RPMI 1640 medium (Life Technologies, The Netherlands) supplemented with 2% 
heat-inactivated fetal calf serum (FCS). To induce NETosis, neutrophils were stimulated for 3.75 
hours with one of the following: medium (negative control), 10% serum, 10% IgG-depleted serum, 
250 or 25 µg/ml IgG, 25 nM phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich, Saint-Louis, MO, 
USA) or IgG derived from intravenous immunoglobulin (IVIG; Sanquin, Amsterdam, the Netherlands), 
healthy controls and patients. When immobilized IgG was used, 10 µg/ml IgG was coated overnight 
at 4⁰C in a 96-well Falcon plate, after which neutrophils were incubated in the wells. After 
stimulation, 1 µM of the impermeable DNA dye SYTOX green (Thermo Fisher, Waltham, MA, USA) 
was added for 15 minutes and then the neutrophils were fixed with 4% paraformaldehyde (PFA) 
(Added Pharma, Oss, the Netherlands).  
 
2.4. NET visualization and quantification 
NETs were visualized by confocal laser scanning microscopy (CLSM) using the automated BD 
Pathway 855 (BD Biosciences, San Jose, CA, USA), as described previously[35]. Briefly, 12 z-stacked 
images of 25 predefined high-power fields (HPFs) at 20x magnification were automatically captured. 
The HPFs were evenly spread throughout the well using a standardized 5×5 zig-zag pattern that 
accounts for 11.1% of the area of the well. The microscope was programmed to automatically focus 
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on PKH26 membrane staining. PKH26 (Cy3; named after its discoverer Paul Karl Horan) and SYTOX 
green (alexa488) were visualized for each image. The same exposure time was used for all images in 
the same experiment. Acquired images were analyzed automatically with ImageJ software (NIH, 
Bethesda, MD, USA) by determining the area of PKH and the area of extracellular DNA, using a pixel 
threshold to exclude potential intracellular DNA staining. The extracellular DNA of NETs was 
quantified as the cumulative area of positive SYTOX green staining. To correct for the number of 
neutrophils, the mean area of positive PKH26 staining was quantified. Next, the ratio of both areas is 
calculated, representing the NET area corrected for the amount of imaged neutrophils in each 
sample. Quantification of the NET induction data is expressed as the fold induction relative to the 
mean NHS values in each experiment. The correlation of NET induction with the SLEDAI and anti-
dsDNA titers was assessed by Pearson and Spearman correlation coefficients. 
 
2.5. Fluorescence immunocytochemistry of NETs 
Neutrophils were seeded onto chambered coverslips (ibiTreat, Ibidi, Martinsried, Germany), and 
NETs were induced as described above. Fixed neutrophils were blocked with 1% BSA and 20% 
normal goat serum (NGS) in PBS with 5 mM EDTA to inhibit nuclease activity and then stained with 1 
µg/ml polyclonal rabbit anti-human citrullinated histone H3 (Abcam, Cambridge, UK), 5 µg/ml 
polyclonal rabbit neutrophil elastase (NE) (Abcam), or a polyclonal rabbit IgG isotype control (Dako, 
Santa Clara, CA, USA) in PBS plus 1% NGS with 5 mM EDTA and incubated for two hours. The 
neutrophils were then washed and incubated with a 1:500 secondary goat anti-rabbit Alexa488 
antibody (Thermo Fisher). The secondary antibodies were pre-incubated for 30 minutes with 5% 
normal human serum (NHS) to bind anti-human immunoglobulins. After incubation for 60 minutes 
with the secondary antibodies and 1:100 phalloidin (Sigma-Aldrich), neutrophils were washed and 
stained with 1 µg/ml Hoechst 33258 (Thermo Fisher). Images were acquired with the Leica DMI6000 
inverted microscope using a 20x magnification. 
 
2.6. High sensitivity flow cytometry 
Peripheral blood mononuclear cells (PBMCs) were isolated from fresh blood collected in EDTA-
coated tubes using density gradient centrifugation with Ficoll-amidotrizoate (LUMC). At least one 
million events were stained with the following antibodies in 6 different panels for FACS staining: CD3 
(SK7), CD8 (SK1), CD11B (ICRF44), HLA-DR (G46-6), all from BD Biosciences, and CD4 (SK3), CD14 
(MφP9), CD16 (CB16), CD19 (SJ25C1), CD20 (2H7), CD21 (HB5), CD24 (SN3 A5-2H10), CD27 (O323), 
CD38 (HB7), CD56 (B159), CD66B (G10F5), IgM (SADA4), and IgD (IA6-2), all from eBioscience 
(Thermo Fisher Scientific). Cells were read on LSRII (Becton Dickinson, San Jose, CA, USA) and 
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analyzed with Flowjo (Ashland, Oregon, USA). B-cells were defined as CD3-CD19+ cells, wherein 
memory B-cells were CD27+cells, transitional B-cells were CD24brightCD38bright cells, and circulating 
plasma cells were CD38brightCD27bright cells. Absolute cell numbers were calculated using the absolute 
lymphocyte counts. 
 
2.7. Autoantibody measurements 
Anti-dsDNA autoantibodies were semi-quantitatively measured using the in-house, Crithidia luciliae 
indirect fluorescent test (CLIFT). For quantitative measurements of anti-dsDNA, anti-U1RNP, anti-
RNP70 and anti-Sm (anti-ENA) autoantibody serum levels Phadia 250 (Thermo Fisher, Waltham, MA, 
USA) was used. This is a fully automated and high-throughput system using fluorescence enzyme 
immunoassay for routine laboratory testing where the fluorescence signal of measured serum 
samples is compared to calibrators with known concentrations. Anti-C1q levels were determined 
using commercially available ELISA (Inova, San Diego, CA, USA) according to the manufacturer’s 
instructions. 
 
2.8. Measuring serum levels of free BlyS 
The assay to quantify free BLyS is a bespoke assay, developed and validated as fit for purpose at 
GlaxoSmithKline (GSK) with sera from patients treated with belimumab.  Briefly, the capture 
reagent, biotinylated-belimumab-antibody fragment (Fab), is bound to a microtiter streptavidin-
coated 96-well plate. BLyS, in the diluted serum sample, is captured by binding to the biotinylated-
drug-Fab and detected by the addition of Alexa-Fluor labeled goat anti-BLyS polyclonal antibody. The 
plate is washed and Elution Buffer B is added for acidification, thereby cleaving the Alexa labelled 
antibody.  Neutralization Buffer C is added to a new 384-well plate.  The eluate is then transferred 
from the 96-well assay plate to a 384-well plate.  The 384-well plate is then read on the Erenna 
immunoassay system (Singulex, Alameda, CA, USA). The concentration of free BLyS in serum samples 
is interpolated from a reference standard curve.  One signal (DE, PE, or TP) is chosen for export and 
analysed within Softmax GxP (Molecular Devices, San Jose, CA, USA).  
 
2.9. Statistical analysis 
All data are reported as individual data points or as median [range]. Differences between week 0 and 
week 24 or between two groups were compared using a nonparametric paired t-test. Correlations 
were assessed using Pearson and Spearman correlation coefficient. All statistical analyses were 





3.1. Patient characteristics 
A therapeutic approach that targets B-cells with RTX+BLM was investigated to determine its 
immunological effects on humoral autoimmunity in SLE patients. To do so, we included 16 patients 
with severe refractory SLE from a total of 31 screened patients in this study. Patient characteristics 
are shown in Table 1. Briefly, the majority of SLE patients was female and had severe disease with 
major organ involvement. The median [range] SLEDAI was 18 [6–29] and 13 patients (81%) had 
active lupus nephritis (LN) with a median [range] proteinuria of 2.3 g/day [1–8.2]. One patient had 
transverse myelitis at inclusion and presented with paralysis of the lower extremities. All patients 
had refractory disease with a median of 3 relapses that had failed to respond to previous treatment 
with mycophenolate acid and at least one other immunosuppressive regimen.   
 
Table 1. Baseline and historic disease characteristics of patients in the SynBioSe study (n=16) 
Demographics   
Age, median (range) 31 (19-51) 
Female sex, n (%) 14 (88) 
Race, n (%)   
 White/Caucasian 5 (31) 
 Black/African American 10 (63) 
 Asian/Oriental 1 (6) 
Smoker, n (%) 3 (19) 
   
Baseline disease characteristics   
SLEDAI, median (range) 18 (6-29) 
Disease flare characteristics, n (%)   
 Renal flare  13 (81) 
 Transverse myelitis 1 (6) 
 Persistent disease activity despite treatment 2 (13) 
    
LN disease characteristics (n=13)   
Histopathology, n (%)   
 Class II (±V) 1 (8) 
 Class III (±V) 4 (31) 
 Class IV (±V) 5 (38) 
 Class V 3 (23) 
Proteinuria (g/24h), median (range) 
 
2.3 (1.0-11.2) 
Treatment at disease flare    
Glucocorticoids*, n (%) 13 (81) 
       Dose mg/day, median (range)  15 (5-60) 
Mycophenolate mofetil, n (%) 10 (63) 
       Dose mg/day, median (range) 2000 (1000-4000) 
Azathioprine, n (%) 3 (19) 
       Dose mg/day, median (range) 150 (100-200) 
Hydroxychloroquinine, n (%) 
 
12 (75) 
   
Biomarkers   
ANA positivity 16 (100) 
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Anti-dsDNA titer (IU/ml)†, median (range) 144 (18-505) 
Complement consumption‡ (%)  16 (100) 
C3§ (g/l), median (range) 0.6 (0.3-1.3) 
C4¥ (mg/l), median (range) 96 (21-260) 
IgG (g/l), median (range) 11.5 (4.9-23.6) 
IgA (g/l), median (range) 3 (1.2-6.3) 
IgM (g/l), median (range) 0.7 (0.3-1.1) 
CD19+ B-cells (*106 cells/l), median (range) 100 (21-302) 
   
Historic disease characteristics   
Disease duration in years, median (range)   10 (2-24) 
No. of previous relapses, median (range) 3 (1-6) 
No. of renal relapses, median (range) 1 (0-5) 
SLICC damage index, median (range) 1 (0-4) 
Organ involvement, n (%)   
       Constitutional 16 (100) 
       Mucocutaneous  13 (81) 
       Neuropsychiatric  2 (13) 
       Musculoskeletal  10 (63) 
       Cardiorespiratory  11 (69) 
       Gastrointestinal  0 (0) 
       Opthalmic  2 (13) 
       Renal 15 (94) 
       Hematology  10 (63) 
   
Treatment history    
Steroids, n (%) 16 (100) 
Mycophenolate mofetil, n (%) 16 (100) 
Cyclophosphamide, n (%) 7 (44) 
Azathioprine, n (%) 9 (56) 
Tacrolimus, n (%) 1 (6) 
Rituximab, n (%) 4 (25) 
Hydroxychloroquinine, n (%) 14 (88) 
*Patients were treated with the glucocorticoid equivalent prednisolone. †Normal anti-dsDNA IgG 
<10 IU/ml. ‡Complement consumption is defined as decreased CP (classical pathway) activation, 
decreased C3 or decreased C4. §Normal C3: 0.9-2 g/l. ¥Normal C4: 95-415 mg/l.  
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; LN, Lupus Nephritis; ANA, Anti-
Nuclear antibodies; SLICC, Systemic Lupus International Collaborating Clinics. 
 
3.2. RTX+BLM specifically reduces humoral autoimmune phenomena in refractory SLE patients  
First, we confirmed the hypothesis that belimumab effectively inhibited a spike of circulating BlyS 
after B-cell depletion. Indeed, by quantifying free circulating BlyS levels (Figure 1A) we observed a 
significant increase of serum BlyS levels at 4 weeks ( 1.17 ng/ml [0.02-4.81]) after initiation of 
rituximab compared to baseline levels (1.08 ng/ml [0.14-3.22], P=0.03). Belimumab treatment 
thereafter effectively reduced BlyS levels to 0.15 ng/ml [0.05-0.4], P<0.01, at 24 weeks. 
 
Second, we used high sensitivity flow cytometry to monitor the kinetics of different B-cell subsets in 
SLE patients treated with RTX+BLM. We observed that B-cells were significantly depleted from 
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100×106 cells/liter [21–302×106] at baseline to a nadir of 2.43×106 cells/liter [1.17–8.0×106] 
(P<0.0001) equal to 98% decrease from baseline. At 24 weeks, the B-cells had repopulated to a level 
of 11×106 cells/liter [0.5–64.7×106] (P=0.0002) (Supplementary Table 1), which still represented 94% 
decrease (Figure 1B). B-cell subset analysis demonstrated that memory B-cells were depleted from 
17.5×106 cells/liter [6.2–142] at baseline to a nadir of 1.34×106 cells/liter [0.15–4.4] (P=0.0001) equal 
to 94% decrease. Transitional B-cells were completely depleted from 0.93×106 cells/liter [0.08–3.43] 
at baseline to a nadir of 0 [0–0.15×106] (P=0.0002) representing 100% decrease. Circulating plasma 
cells were depleted from 2.13×106 cells/liter [0.07–10.5×106] at baseline to a nadir of 0.11×106 
cells/liter [0–11×106] (P=0.104) equal to 95% decrease. Looking more closely at B-cell subsets during 
repopulation at 24 weeks, memory B-cells were the dominant subset, with 4.46×106 cells/liter [0.31–
49.5×106] equal to 76% decrease from baseline. Circulating plasma cells repopulated to 1.26×106 
cells/liter [0–18.3×106] equal to 72% decrease from baseline. Transitional B-cells did not repopulate 
and remained depleted at a level of 0×106 cells/liter [0–6.22×106] at 24 weeks (Figure 1B).  
 
Third, we assessed the effects of RTX+BLM on (auto-)antibody levels (Figure 2 and Supplementary 
Table S1). Total IgG levels transiently declined from baseline levels of 11.5 g/l [4.8–23.6] to 8.1 g/l 
[2.6–14.4] at week 12 (P=0.03) and returned to 8.9 g/l [3.4–16.4] at week 24 (P=0.12). A median 
decrease of 21% from baseline was observed at week 24 (Figure 2A). Of note, IgM levels steadily 
decreased from baseline levels of 0.7 [0.3–1.1] to 0.4 g/l [0.2–0.7] at week 24 (P=0.0007). IgA levels 
had not significantly changed at week 24. Anti-tetanus toxoid (Figure 2B), anti-rubella (Figure 2C) 
and anti-varicella zoster virus (Figure 2D) antibody levels did not change significantly during 
treatment. Based on the fluorescence enzyme immunoassay, 12 out of 16 patients were anti-dsDNA 
positive at baseline with a median anti-dsDNA level of 144 IU/ml [range 18–505]. Following 
RTX+BLM treatment, the anti-dsDNA levels steadily decreased to 57 IU/ml [10–374, P=0.0004] at 
week 24. We found a median decrease in anti-dsDNA antibody levels of 58% (Figure 2E). Seven out 
of 12 (58%) anti-dsDNA positive patients had converted to negative immunofluorescence at week 
24. Additionally, based on immunofluorescence, 7 patients were positive for anti-Sm autoantibodies, 
6 patients for anti-RNP70 autoantibodies and 9 patients for anti-U1RNP autoantibodies at baseline. 
Anti-Sm antibody levels decreased by 35% (Figure 2F), anti-RNP70 antibody levels by 48% (Figure 2G) 
and anti-U1RNP antibody levels by 58% (Figure 2H) at week 24. Fourteen of 16 patients (88%) had 
anti-C1q autoantibodies and anti-C1q antibody levels decreased by 45% at week 24 (Figure 2I). To 
assess whether RTX+BLM specifically targeted autoantibody levels, the ratios of (auto-)antigen-
specific antibodies to total IgG levels were determined in individual patients (Figure 2J), 
demonstrating preferential reductions of autoantibodies. 
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Fourth, we investigated systemic complement activation: C3 and C4 levels and classical pathway (CP) 
activity were reduced in all patients at baseline. The reduced C3 concentrations were restored to 
normal levels within 24 weeks after RTX+BLM treatment in 6 out of 14 patients. Overall, the C3 
levels increased from 0.6 g/l [0.3–0.8] at baseline to 0.8 g/l [0.5–1.3] at week 24, P=0.002 
(Supplementary Table S1). Reduced C4 concentrations were restored to normal levels within 24 
weeks in 5 out of 8 patients; overall, C4 levels increased from 54 [21–80] at baseline to 110 mg/l 
[39–292] at week 24, P=0.04. CP activity had normalized in 8 out of 14 patients at week 24. Overall, 
complement activation had normalized in 7 out of 15 (47%) patients at week 24.  
 
Taken together, these data demonstrate that RTX+BLM treatment led to complete but transient B-
cell depletion, with early repopulation of memory B-cells and circulating plasma cells. RTX+BLM 
specifically reduced relevant circulating SLE-specific autoantibodies and improved complement 
profiles, which suggests that RTX+BLM effectively targets humoral autoimmune phenomena in SLE 
patients. 
 
3.3. Excessive NET formation is normalized upon RTX+BLM treatment  
Based upon previous reports that SLE-specific autoantibodies were demonstrated to induce 
excessive NET formation in vitro [4] due to crosslinking of Fc-gamma receptors (FcγRs) by pathogenic 
immune complexes (ICx) [2], we investigated whether reducing ANAs also resulted in a regression of 
NET formation in our patients with severe SLE. Representative images of ex vivo NET formation 
before and after RTX+BLM in 2 patients are shown in Figure 3A. In our study population, excessive 
NET formation was observed at baseline, which was 6.8-fold [2.6–12.8] increased compared to NHS 
controls (P<0.0001) (Figure 3B). RTX+BLM treatment significantly diminished excessive NET 
formation at 12 weeks and at 24 weeks: 1.6 fold [0.9–13.7] (P=0.003) and 1.9 fold [0.4–6.1] 
(P=0.0006), respectively. These data show that RTX+BLM treatment regressed excessive NET 
formation in severe SLE patients. 
 
3.4. RTX+BLM leads to beneficial clinical responses in refractory SLE patients  
Finally, we investigated whether the observed immunological effects translated into clinical disease 
amelioration. Ten patients, 9 patients with active lupus nephritis and 1 patient with transverse 
myelitis, received concomitant pulse intravenous glucocorticoids prior to rituximab. All 16 patients 
received RTX+BLM according to the study protocol. At baseline, the median SLEDAI was 18 [6–29] 
and this significantly decreased to a median SLEDAI of 2 (0–13, P<0.0001) at week 24 (Figure 4A). 
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LLDAS was achieved in 10 patients at week 24. Three patients were classified as non-responders. 
One patient showed persistent disease activity of SLEDAI 13 at week 24, including persistent 
complement activation, positivity for anti-dsDNA antibodies, proteinuria, hematuria and pyuria. 
Importantly, this patient did not achieve B-cell depletion after RTX due to preformed human anti-
chimeric antibodies (HACAs). A second patient showed increased complement activation, positivity 
for anti-dsDNA antibodies, and persistent proteinuria at week 24. This patient was treated with 
methylprednisolone and high-dose glucocorticoids for active LN at baseline and developed a severe 
mood disorder and psychosis for which the glucocorticoids had to be abruptly reduced to 10 mg. The 
third patient dropped out of the study at 8 weeks due to severe hypogammaglobinemia (IgG nadir of 
1.8 g/l), requiring intravenous immunoglobulin treatment. Notably, this patient also received pulse 
intravenous glucocorticoids. In the 13 patients with LN, a renal response was observed in 11, with 5 
complete responders. In these patients, the median proteinuria levels at baseline of 2.3 g/24h [range 
1–11.2] significantly decreased to a median of 0.7 g/24h [0.1–1.8] at 24 weeks (P=0.0005) (Figure 
4B). 
 
These clinical responses were achieved during RTX+BLM treatment while tapering concomitant 
immunosuppressive medication. In 14 patients who were treated with glucocorticoids, the median 
baseline glucocorticoid dose of 60 mg/day [5–60] was successfully tapered to a median dose of 7.5 
mg/day [5–12.5], P=0.001 (Figure 4C). Only one patient was still treated with >7.5 mg/day 
glucocorticoids at week 24. Additionally, 10 out of 16 patients were on MMF at baseline which was 
stopped successfully in all patients (Figure 4D). In 5 out of 10 patients on MMF, tapering of MMF was 
started after 8 weeks and in the other 5 patients, tapering was started before 8 weeks. In the patient 
who developed a glucocorticoid-induced severe mood disorder and psychosis, MMF treatment was 
started at 4 weeks and continued throughout the study. There was also a significant improvement in 
systemic inflammatory markers as measured by the erythrocyte sedimentation rate (ESR) and 
leukocyte counts during RTX+BLM treatment (Supplementary Table S1). Compared to baseline 
values, the median ESR decreased from 47 mm [6–129] to 19 mm [2–77] at 24 weeks (P=0.02).  
As mentioned above, autoantibody levels (see also Supplementary Table S1), complement activation 
(see also Supplementary Table S1) and ex vivo NET formation all significantly improved in response 
to RTX+BLM treatment. Strikingly, ex vivo NET formation showed a significant correlation with 
SLEDAI (r=0.52, P=0.0003) (Figure 4E) that was stronger than the weak correlation between 
circulating anti-dsDNA autoantibody levels and SLEDAI (r=0.34, P=0.03) (Figure 4F). 
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The safety profile of RTX+BLM is summarized in Table 2. Briefly, 41 treatment-emergent adverse 
events (AEs) were observed. All patients experienced at least 1 adverse event. Hospitalization for 
self-limiting viral gastroenteritis classified as major infection. Twelve (38%) minor infections were 
observed and circulating HACAs in 4 patients. Hypogammaglobulinemia was observed in 3 patients 
and led to the withdrawal of one patient. In a second patient, IgG levels decreased to 2.5 g/l with 
symptoms of viral sinusitis responding to increasing BLM treatment interval to 8 weeks for 3 




Table 2. Adverse events during 24 weeks of study  
  
Any adverse events*, n (%) 
 
41  
Major infection (hospitalisation) , n (%) 1  (2%) 
Minor infection, n (%) 
  
15  (37%) 
       Upper respiratory tract 
 
6  
       Lower respiratory tract  3  
       Urinary tract   3  
       Sinusitis    1  
       Influenza    1  
       Herpes simplex   1  
HACA formation, n (%)¶ 
  
4  (10%) 
       Symptomatic¥   
 
1  
       Asymptomatic¥  
 
3  
Hypogammaglobulinemia† (<4.0 g/l), n (%) 3  (7%) 
Glucocorticoid-induced mood disorder/ psychosis, n (%) 1  (2%) 
Diarrhoea, n (%) 
  
5  (12%) 
Myalgia, n (%) 
  
3  (7%) 
Infusion-related reaction, n (%) 
 
2  (5%) 
Headache, n (%) 
  
1  (2%) 
Nausea, n (%) 
  
1  (2%) 
Other‡, n (%)        5  (12%) 
*Treatment-emergent adverse events. †Study agent was interrupted in one patient, one patient was 
excluded from the study. ‡Other events include: iron deficiency anemia, rash, onycholysism, 
hyperkalemia, dry eyes.  
¶HACA, human anti-chimeric antibodies, as quantified by using validated antigen-binding tests(RIA). 
¥ Patients with HACA formation were classified as symptomatic when clinical signs of serum sickness 
were observed in conjunction with a newly positive test for HACAs. Patients were classified as 






This translational proof-of-concept study is the first clinical trial to investigate the immunological and 
clinical responses of RTX+BLM in patients with severe, refractory SLE. Recently we found that 
circulating ICx contributed to excessive NET formation in SLE in line with data from others [2,4]. Here 
we now  demonstrate that RTX+BLM effectively reduced ANAs and regressed excessive NET 
formation ex vivo while achieving significant clinical responses in patients with severe refractory SLE. 
As such, we describe the unique finding that B-cell targeting by RTX+BLM indirectly affected 
neutrophils when assessing NET formation. Even though a proper control group was lacking, this 
study provides novel insight into the autoimmunity of SLE with respect to NETs and ANA formation 
and puts forward a new therapeutic concept to target this pathophysiology. 
 
Our study showed preferential reductions of autoantibody levels compared to physiological antibody 
levels suggesting that autoantibody-secreting plasma cells are more susceptible to RTX+BLM. 
Interestingly, after RTX+BLM led to profound B-cell depletion, early repopulation was dominated by 
memory B-cells and circulating plasma cells in the absence of the reconstitution of transitional B-
cells. These observations suggest that early repopulation after RTX+BLM is derived from the 
recruitment of differentiated B-cells from lymphoid tissues rather than reconstitution from 
precursor B-cells from the bone marrow. These observations corroborated findings in patients 
treated with belimumab only where an increase in memory B-cells was observed [26,36,37]. These 
data support the hypothesis that neutralizing BAFF in the context of B-cell depletion can result in 
migration of tissue-resident mature B-cells into the circulation.  
 
The present study was designed to investigate the feasibility of RTX+BLM in severe SLE patients 
while simultaneously studying the thus far unknown immunological effects. At the time of the 
study’s design, it was considered unethical to randomize severe, refractory patients to either a RTX 
only arm, which failed to be superior over conventional treatment these patients already failed[18] 
or a BLM only arm which was not investigated in severe SLE patients. Despite this limitation, we 
observed significant clinical responses in previously unremitting, treatment- refractory SLE patients: 
on SLEDAI and LLDAS was achieved in 75% while tapering concomitant immunosuppression. Of note, 
LLDAS associated with lower damage accrual [34,38]. As such, this proof-of-concept study is an 
important stepping stone to further study RTX+BLM in SLE patients.  
 
5. Conclusion 
We demonstrated that RTX+BLM ameliorated autoimmune phenomena by reducing circulating ANAs 
and regressing ICx-mediated excessive NET formation in SLE. Simultaneously, RTX+BLM elicited 
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significant clinical responses in patients with severe, refractory SLE. RTX+BLM therapy represents a 
promising new treatment concept that specifically targets pathological autoimmunity in SLE 
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RTX+BLM specifically reduces humoral autoimmune phenomena in refractory SLE patients. (A) The 
percentage change of free serum BlyS in individual patients throughout the 24-week study. The thick 
black line represents the median and thin grey lines represent individual data. (B) The median 
change from baseline in the number of circulating B-cells (CD19+), memory B-cells (CD3-
CD19+CD27+), transitional B-cells (CD3-CD19+CD38brightCD24bright) and plasma cells (CD3-
CD38brightCD27brightCD19+) as measured in peripheral blood using high sensitivity flow cytometry. 
 
Figure 2 
RTX+BLM specifically reduces autoantibodies in refractory SLE patients. (A) The percentage change 
in the total IgG in individual patients throughout the 24-week study. (B) The percentage change in 
anti-tetanus toxoid (TT), (C) anti-rubella, (D) anti-VZV antibodies (n=16), (E) anti-dsDNA antibodies 
(n=12), (F) anti-Sm antibodies (n=7), (G) anti-RNP70 antibodies (n=6), (H) anti-U1RNP antibodies 
(n=9) and (I) anti-C1q antibodies in individual patients throughout the 24-week study. (J) The median 
normalized ratio of the reference condition anti-TT IgG to the total IgG (black bars), anti-rubella and 
anti-VZV to total IgG, and the normalized ratios of various autoantibodies (anti-dsDNA, anti-RNP70, 
anti-U1RNP, anti-Sm, anti-C1q) to total IgG. Thick black lines represent the median and thin grey 
lines represent individual data. *P<0.05, **P<0.01, ***P<0.001. 
 
Figure 3 
RTX+BLM treatment significantly reduces excessive ex vivo NET formation. (A) Representative 
images of ex vivo NET formation at week 0, week 12 and week 24 in 2 patients. Extracellular DNA is 
stained with SYTOX (green) and cells are labelled with the membrane stain PKH26 (red). Bars = 100 
μm. (B) Ex vivo NET formation in SLE patients during RTX +BLM treatment. The dotted line 
represents the normal human serum (NHS) control. Data are expressed as fold increase compared to 
the NHS control. Each point represents one patient, solid lines represent the median fold induction. 
**P<0.01, ***P<0.001. 
 
Figure 4  
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Beneficial clinical responses in refractory patients treated with RTX+BLM. (A) SLE Disease Activity 
Score (SLEDAI) at weeks 0, 4, 12, and 24. (B) Proteinuria (g/day) at weeks 0, 12, and 24 in patients 
with active lupus nephritis at baseline (n=13). (C) Successful tapering of glucocorticoids in patients 
on glucocorticoids at baseline (n=14), in mg/day prednisolone. (D) Successful discontinuation of 
mycophenolate mofetil (MMF) within 24 weeks of treatment in patients treated with MMF at 
baseline (n=10). Correlation of SLEDAI scores with NET formation (E) and with anti-dsDNA titers (F). 
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